financetom
Business
financetom
/
Business
/
XTM Sells QRails Processing Technology for US$3 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
XTM Sells QRails Processing Technology for US$3 Million
May 25, 2025 8:52 PM

09:50 AM EDT, 04/29/2025 (MT Newswires) -- XTM (PAID.CN) on Tuesday said it sold its QRails processing technology to a subsidiary of Digital Commerce Group for US$3 million.

The fintech company expects the transaction to reduce its monthly operating costs by around 50%, positioning it to reach cash neutrality by the third quarter. XTM expects the transaction to close within the next ten business days, pending customary bank and network approvals.

A statement further noted that the company would retain full ownership and management of its proprietary Earned Wage Access platform, including key contracts, integrations with payroll, time & attendance, and other critical systems. The company added that after the close of the transaction, XTM will fully repay the Earned Wage Access funding provided by Two Shores, and settle all interest obligations associated with long-term debt.

Additionally, the company also reported the dissolution of its previously announced referral agreement with KOHO, saying that it would revert approximately 10,000 AnyDay members who transitioned to KOHO earlier this year back to the AnyDay platform, with full migration expected by June 30.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
Apr 3, 2025
(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's ( AMGN ) drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in...
Analysis-Mexico free trade with US may survive as Trump spares it from new tariffs, hits rivals
Analysis-Mexico free trade with US may survive as Trump spares it from new tariffs, hits rivals
Apr 3, 2025
MEXICO CITY (Reuters) - President Donald Trump's Liberation Day appeared set to end North American free trade and Mexico's privileged access to the U.S.  Instead, Mexican officials are celebrating being left off Trump's global tariffs list, with analysts suggesting the omission could prolong North American free trade.  On a day in which nearly all countries were hit with at least...
Sector Update: Consumer
Sector Update: Consumer
Apr 3, 2025
03:35 PM EDT, 04/03/2025 (MT Newswires) -- Consumer stocks were mixed late Thursday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) rising 0.6% and the Consumer Discretionary Select Sector SPDR Fund (XLY) dropping 6.1%. In sector news, President Donald Trump's auto tariffs will likely cost US car buyers about $30 billion in the first year, assuming carmakers will...
Stellantis to idle Michigan plant for several weeks due to engine shortage
Stellantis to idle Michigan plant for several weeks due to engine shortage
Apr 3, 2025
April 3 (Reuters) - Chrysler-parent Stellantis ( STLA ) said on Thursday it is idling a plant in Warren, Michigan, for several weeks due to a shortage of engines. It said the issue is unrelated to new U.S. auto tariffs. The automaker said it is allocating all available engines to support production of the Ram 1500 at the Sterling Heights...
Copyright 2023-2025 - www.financetom.com All Rights Reserved